Martin Kaiser, MD, FRCP, FRCPath

Professor
The Royal Marsden and The Institute of Cancer Research, London, UK, United Kingdom

Poster(s):

• (306) Life-year and quality-adjusted life-year results from a United States cost-effectiveness model for belantamab mafodotin, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma
  Wednesday, October 29, 2025